Alx Oncology Holdings Inc (ALXO)

$2.18 +0.27 (14.14%)
Market Cap 116.74M
Revenue (ttm) 0.00
Net Income (ttm) -134.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.16
Volume 1,073,400
Avg Vol 1,104,414
Day's Range N/A - N/A
Shares Out 53.55M
Stochastic %K 94%
Beta 1.21
Analysts Strong Sell
Price Target $2.25

Company Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 466 7125
Address:
323 Allerton Avenue, South San Francisco, United States
highnihilism
highnihilism Oct. 5 at 9:29 AM
$ALXO Alx Oncology (52-week highs & lows) 2.18 +0.27 +14.1% | 52-week low 0.40 | 52-week high 2.05 volume (oct 3) 1,051,229 | market cap 116.7 m | avg option vol 130
0 · Reply
Bullisch_150
Bullisch_150 Oct. 4 at 10:25 AM
$ALXO Cash until 2027 and few shares outstanding. This biotech gem has everything it takes to quickly reach $20 and beyond!
1 · Reply
Bullisch_150
Bullisch_150 Oct. 4 at 10:24 AM
$ALXO monday we going open with 3$
0 · Reply
Groin
Groin Oct. 3 at 7:45 PM
$ALXO Enjoy the ride
0 · Reply
Bullisch_150
Bullisch_150 Oct. 3 at 7:42 PM
$ALXO monsterstock
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 3 at 7:42 PM
$ALXO has soared 4% higher to 17% (~858Kv) a moment ago, 10/17 options, follow for more volatility.
0 · Reply
Arthur_PL
Arthur_PL Oct. 3 at 7:27 PM
$ALXO Guys those shares growing so fast. Any price prediction?
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Oct. 3 at 7:21 PM
$ALXO just a bear tard
0 · Reply
smoketuna
smoketuna Oct. 3 at 7:11 PM
$ALXO 83% with 🎯 TunaSignal.ai score! while price $1.83 - Catch the Big Movers Before They Break Out - Powered by AI
0 · Reply
P119
P119 Oct. 3 at 2:11 PM
$ALXO who the heck 500k block
0 · Reply
Latest News on ALXO
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 3, 2025, 9:05 AM EDT - 1 day ago

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

Sep 12, 2025, 8:30 AM EDT - 22 days ago

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

ALX Oncology to Participate in Upcoming Investor Conferences in September

Aug 29, 2025, 12:00 PM EDT - 5 weeks ago

ALX Oncology to Participate in Upcoming Investor Conferences in September

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

Aug 19, 2025, 8:00 AM EDT - 6 weeks ago

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 9:45 PM EDT - 7 weeks ago

ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:05 PM EDT - 7 weeks ago

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

Aug 5, 2025, 8:00 AM EDT - 2 months ago

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

May 30, 2025, 8:00 AM EDT - 4 months ago

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

May 20, 2025, 8:00 AM EDT - 4 months ago

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

May 13, 2025, 8:00 AM EDT - 5 months ago

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 8:30 AM EDT - 5 months ago

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025, 8:00 AM EDT - 5 months ago

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

Apr 25, 2025, 1:10 PM EDT - 5 months ago

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

Apr 25, 2025, 9:00 AM EDT - 5 months ago

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 6, 2025, 4:01 PM EST - 7 months ago

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

Mar 5, 2025, 8:00 AM EST - 7 months ago

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 27, 2025, 8:00 AM EST - 7 months ago

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

ALX Oncology to Host Virtual R&D Day on March 5, 2025

Feb 18, 2025, 8:00 AM EST - 8 months ago

ALX Oncology to Host Virtual R&D Day on March 5, 2025

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

Jan 23, 2025, 8:00 AM EST - 9 months ago

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

Jan 22, 2025, 4:01 PM EST - 9 months ago

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

Jan 21, 2025, 5:00 PM EST - 9 months ago

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

Dec 18, 2024, 8:00 AM EST - 10 months ago

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

Nov 14, 2024, 8:00 AM EST - 11 months ago

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 4:00 PM EST - 11 months ago

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

Nov 1, 2024, 5:30 PM EDT - 1 year ago

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

Sep 11, 2024, 10:36 PM EDT - 1 year ago

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

Aug 6, 2024, 4:01 PM EDT - 1 year ago

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

Jul 31, 2024, 4:01 PM EDT - 1 year ago

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Jul 31, 2024, 5:30 AM EDT - 1 year ago

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Jun 27, 2024, 4:13 AM EDT - 1 year ago

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

Jun 2, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

May 29, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 4:00 PM EDT - 1 year ago

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Appoints Allison Dillon as Chief Business Officer

May 7, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Appoints Allison Dillon as Chief Business Officer

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Apr 24, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

Apr 9, 2024, 5:30 PM EDT - 1 year ago

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 7, 2024, 4:03 PM EST - 1 year ago

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 1 year ago

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

ALX Oncology shares jump 9% after Jefferies upgrade

Dec 8, 2023, 8:30 AM EST - 1 year ago

ALX Oncology shares jump 9% after Jefferies upgrade

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 4:05 PM EST - 2 years ago

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 10, 2023, 4:05 PM EDT - 2 years ago

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

Oct 9, 2023, 12:38 AM EDT - 2 years ago

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

ALX Oncology Announces Pricing of Public Offering

Oct 5, 2023, 8:00 AM EDT - 2 years ago

ALX Oncology Announces Pricing of Public Offering

ALX Oncology Announces Proposed Public Offering

Oct 4, 2023, 4:10 PM EDT - 2 years ago

ALX Oncology Announces Proposed Public Offering

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Oct 3, 2023, 6:00 AM EDT - 2 years ago

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Oct 2, 2023, 4:05 PM EDT - 2 years ago

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

ALX Oncology Realigns Executive Leadership Team

Sep 6, 2023, 8:00 AM EDT - 2 years ago

ALX Oncology Realigns Executive Leadership Team

ALX Oncology Announces September Investor Conference Participation

Aug 31, 2023, 7:00 AM EDT - 2 years ago

ALX Oncology Announces September Investor Conference Participation

ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

Aug 10, 2023, 4:01 PM EDT - 2 years ago

ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

Jun 26, 2023, 7:00 AM EDT - 2 years ago

ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

highnihilism
highnihilism Oct. 5 at 9:29 AM
$ALXO Alx Oncology (52-week highs & lows) 2.18 +0.27 +14.1% | 52-week low 0.40 | 52-week high 2.05 volume (oct 3) 1,051,229 | market cap 116.7 m | avg option vol 130
0 · Reply
Bullisch_150
Bullisch_150 Oct. 4 at 10:25 AM
$ALXO Cash until 2027 and few shares outstanding. This biotech gem has everything it takes to quickly reach $20 and beyond!
1 · Reply
Bullisch_150
Bullisch_150 Oct. 4 at 10:24 AM
$ALXO monday we going open with 3$
0 · Reply
Groin
Groin Oct. 3 at 7:45 PM
$ALXO Enjoy the ride
0 · Reply
Bullisch_150
Bullisch_150 Oct. 3 at 7:42 PM
$ALXO monsterstock
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 3 at 7:42 PM
$ALXO has soared 4% higher to 17% (~858Kv) a moment ago, 10/17 options, follow for more volatility.
0 · Reply
Arthur_PL
Arthur_PL Oct. 3 at 7:27 PM
$ALXO Guys those shares growing so fast. Any price prediction?
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Oct. 3 at 7:21 PM
$ALXO just a bear tard
0 · Reply
smoketuna
smoketuna Oct. 3 at 7:11 PM
$ALXO 83% with 🎯 TunaSignal.ai score! while price $1.83 - Catch the Big Movers Before They Break Out - Powered by AI
0 · Reply
P119
P119 Oct. 3 at 2:11 PM
$ALXO who the heck 500k block
0 · Reply
StarLord13
StarLord13 Oct. 3 at 1:47 PM
$ALXO https://alxoncology.gcs-web.com/news-releases/news-release-details/alx-oncology-present-updated-data-phase-2-aspen-06-trial
0 · Reply
StarLord13
StarLord13 Oct. 3 at 1:34 PM
$ALXO Fuck it, picked up another 1000 shares at open. Keeping more dry powder if it breaks lower, but they’re not letting this thing drop.
1 · Reply
StarLord13
StarLord13 Oct. 3 at 12:16 PM
$ALXO Break $2.05 and…
0 · Reply
Groin
Groin Oct. 3 at 9:20 AM
$ALXO Nice cup and handle
0 · Reply
Iorgi
Iorgi Oct. 3 at 8:58 AM
$ALXO whoaaaa. Over 2 today after a nice steady climb. Someone always knows something.
0 · Reply
RunnerSignals
RunnerSignals Oct. 2 at 8:16 PM
market warriors comeback 🔥 $MLTX $LPTH $EPSM $ALXO dipped early but rallied to close strong!
0 · Reply
Groin
Groin Oct. 2 at 8:03 PM
$ALXO 1.91
0 · Reply
PatienceReward
PatienceReward Oct. 2 at 7:55 PM
$ALXO
0 · Reply
MakingMoneyHere
MakingMoneyHere Oct. 2 at 6:45 PM
$ALXO Big pump incoooming
0 · Reply
StarLord13
StarLord13 Oct. 2 at 1:51 PM
$ALXO
0 · Reply
highnihilism
highnihilism Sep. 30 at 11:33 AM
$YUMC Yum China: 54 trades, $29K vs $112K avg (0.26x). $21K calls / $8K puts. $GSBD Goldman Sachs BDC: 33 trades, $25K vs $6K avg (4.38x !!!). $21K calls / $4K puts. $SFIX Stitch Fix: 167 trades, $26K vs $101K avg (0.26x !!). $21K calls / $5K puts. $ALXO Alx Oncology: 56 trades, $21K vs $3K avg (6.78x !!!!). $21K calls / $0 puts.
0 · Reply
MakingMoneyHere
MakingMoneyHere Sep. 29 at 2:05 PM
$ALXO Very low volume, no one wants to buy at these levels...
1 · Reply